Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in Italy: pharmacoeconomic and clinical aspects
Despite considerable improvements in the last two decades, chemotherapy-induced nausea and vomiting (CINV) remains a frequent and very bothersome medical problem. It is estimated that about one half to two thirds of all chemotherapy-treated patients experience CINV, the frequency depending on the ch...
Main Authors: | Lorenzo Pradelli, Mario Eandi |
---|---|
Format: | Article |
Language: | English |
Published: |
SEEd Medical Publishers
2007-06-01
|
Series: | Farmeconomia: Health Economics and Therapeutic Pathways |
Subjects: | |
Online Access: | https://journals.seedmedicalpublishers.com/index.php/FE/article/view/244 |
Similar Items
-
Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
by: Rashad N, et al.
Published: (2017-03-01) -
A case of Mallory-Weiss syndrome secondary to chemotherapy induced nausea and vomiting
by: Afzal SF, et al.
Published: (2016-06-01) -
Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant–palonosetron combination
by: Janicki PK
Published: (2016-05-01) -
Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia
by: Jae Hwa Yoo, et al.
Published: (2018-12-01) -
Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting
by: Mayako Uchida, et al.
Published: (2018-01-01)